They conducted a longitudinal, prospective study on 19 patients with type 2 diabetes, employing 18F-Me-4FDG PET/MRI scans before and after two weeks of SGLT2 inhibitor therapy, while also monitoring blood and urine samples throughout the study. Here, SLC5A2 is linked to type 2 diabetes mellitus.